文献速递医学教育与科研方法

患者信息单对试验干预潜在获益与危害描述程度的差异:一篇评论

Variation in the extent to which patient information leaflets describe potential benefits and harms of trial interventions: a commentary.
PubMed 文献 · Trials · 2025-04-14

该评论基于对247份患者信息单(PIL)的综述,发现28份(11%)未描述潜在获益、23份(9%)未描述潜在危害,描述程度存在差异。作者认为潜在获益与潜在危害之间无原则性差异,未披露可能同时危及自主、不伤害、有利和公正等伦理原则,建议按近期确立的原则统一PIL对获益与危害的描述方式。

要点

  • 247份患者信息单中,28份(11%)未描述潜在获益,23份(9%)未描述潜在危害。
  • 作者认为潜在获益与潜在危害之间不存在原则性差异。
  • 作者建议按近期确立的原则统一患者信息单对获益与危害的描述。

核心结论

  • 患者信息单对试验干预潜在获益与危害的描述程度存在差异,作者建议按近期确立的原则统一描述方式。

研究设计与样本

  • 本文为评论,基于对247份患者信息单(PIL)的综述,总结其对试验干预潜在获益与危害的列出差异并讨论相关伦理问题。

主要发现

  • 247份患者信息单中,28份(11%)未描述潜在获益,23份(9%)未描述潜在危害。
  • 作者认为潜在获益与潜在危害之间不存在原则性差异,即对一个人有帮助的内容可能对另一个人造成危害。
  • 作者指出,未提及潜在危害可能违反自主原则已被认可,而未披露全部潜在获益与危害时其他伦理原则(不伤害、有利、公正)也可能受到威胁,这一点尚不明确。

临床怎么用

  • 作者建议,患者信息单中潜在获益与危害的描述方式应按近期确立的原则进行统一。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trial participants must understand the possible risks and benefits of trial interventions before providing their informed consent to participate. The aim of this commentary is twofold: to summarize the discrepancies in the extent to which patient information leaflets (PILs) list potential benefits and harms of trial interventions; and to highlight subsequent ethical issues that may result from failure to disclose potential benefits or harms . A review of 247 patient information leaflets (PILs) found that the extent to which potential benefits and harms are described varies, with 28 (11%) not describing potential benefits and 23 (9%) not describing potential harms. We argue that there is no principled difference between potential benefits and potential harms (what is helpful for one person could harm another), and the need to disclose potential benefits may be less accepted than the need to disclose all potential harms. Additionally, while it is recognized that failure to mention potential harms may violate the ethical principle of autonomy, it is less well-established that other ethical principles, (the need to avoid harm (non-maleficence) , to help patients (beneficence), and to promote justice) may also be at risk when all potential harms and benefits are not disclosed within PILs. We suggest that the way potential benefits and harms are described within PILs be harmonized according to recently established principles.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Howick J, Lantos JD, Treweek S, et al. Variation in the extent to which patient information leaflets describe potential benefits and harms of trial interventions: a commentary. Trials. 2025. PMID: 40229793. doi:10.1186/s13063-025-08824-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。